Skip to main content

Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications

April 25, 2020

Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in COVID-19 patients.

The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk patients. Patients with conditions like diabetes, heart disease and kidney disease are at higher risk of complications or death due to COVID-19.

The trial will involve 900 patients in the U.S. and globally, said Dr. Mikhail Kosiborod, a cardiologist with the Saint Luke's Mid America Heart Institute and principal investigator for the trial.

Read the full Kansas City Business Journal article: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications

Related Content

KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in Kansas City.